Two Stocks That Could Hit $1 Trillion in Five Years

by

The stock market is a lot like a poker table in a smoky backroom-everyone’s got their eyes on the pot, but only a few know how to play their cards right. Back in 2018, Apple shuffled into the trillion-dollar club, and since then, it’s been a game of musical chairs for the rest of the big players. But here’s the thing: there’s always room for more at this table-if you’re willing to wait long enough.

I’m here to talk about two names that might just pull up a chair in the next five years: Eli Lilly (LLY) and Netflix (NFLX). Both are sitting pretty, but one carries the weight of science, while the other dances to the rhythm of entertainment. Let’s dig in.

A Pharmaceutical Giant with a Bulletproof Script

Eli Lilly isn’t your average drug pusher. No, this company doesn’t deal in dime-a-dozen pills; they peddle miracles. Their golden ticket? Tirzepatide-a compound so potent it makes other medicines look like sugar water. Marketed under Mounjaro for diabetes and Zepbound for weight loss, this stuff has been breaking records faster than a safecracker on a caffeine binge.

Here’s the kicker: most drugs crawl to blockbuster status over decades, limping along like old men with bad knees. Not tirzepatide. It hit the scene in 2022 and already looks set to rake in over $20 billion this year alone. By 2030, projections have it generating $62 billion annually-a number so obscene it makes Pfizer’s pandemic profits look like pocket change.

Loading widget...

Lilly’s growth engine runs hotter than a desert highway in July. In Q2, revenue jumped 38% year-over-year to $15.6 billion. For a pharma giant, that kind of speed feels less like a jog and more like a drag race. And let’s not forget the rest of their lineup-diabetes, obesity, oncology, pain management-they’ve got fingers in every pie.

Then there’s the dividend program, which grows faster than weeds in an abandoned lot. Payouts have doubled in five years, making shareholders feel like they’re sipping champagne instead of swilling coffee. With a current market cap of $660 billion, Lilly needs an 8.67% CAGR to crack the trillion-dollar mark by 2030. Given its trajectory, that doesn’t sound like a pipe dream-it sounds like destiny.

Netflix: The Streaming King Who Refuses to Bow Out

If Eli Lilly is the scientist tweaking formulas in a lab coat, Netflix is the showman pulling rabbits out of hats. Cable TV is dying slower than a sunset, but Netflix isn’t waiting around to write its obituary. Instead, it’s busy stealing eyeballs from living rooms across the globe.

Back in 2019, when Apple and Disney threw their hats into the streaming ring, some thought Netflix would fold like a cheap deck chair. But no. They adapted, launching an ad-supported tier cheaper than a cup of diner coffee and cracking down on password sharing harder than a cop busting a speakeasy. Oh, and they kept raising prices without losing viewers-a feat akin to walking a tightrope blindfolded during a thunderstorm.

Loading widget...

What sets Netflix apart isn’t just its library-it’s the way it creates content tailored to its audience. Every show, every movie, feels like it was made just for you. That’s why people stick around, even as competitors flood the market. Revenue may not be growing at breakneck speeds anymore, but earnings and free cash flow are soaring like eagles chasing the horizon.

With a market cap of $520 billion, Netflix needs a 14% CAGR to join the trillion-dollar club. Is it a stretch? Sure. But if anyone can do it, it’s the streamer with the Midas touch. Even if it falls short, Netflix remains a stock worth holding onto tighter than a gambler clutching his last chip.

Sure, the road ahead is paved with challenges sharper than broken glass. But these two companies are built to weather storms fiercer than a Category 5 hurricane. Whether they reach that magical trillion-dollar milestone or not, they’ll leave plenty of winners in their wake. And maybe, just maybe, you’ll be one of them. 🎯

Read More

2025-08-28 17:44